



2009 Developmental Cancer Research Award in Translational Science

DEAR STANFORD FACULTY,

The Stanford Cancer Center is pleased to announce the availability of grant funds to support the development of interdisciplinary clinical and translational cancer research projects.

The Stanford Cancer Center seeks to stimulate the development of high-quality, multidisciplinary translational cancer research with direct application to cancer diagnosis, treatment, or care. **Projects that feature collaborations between basic scientists, clinical researchers and population researchers, projects lead by junior faculty, innovative clinical trials and projects in GI, prostate and women's cancers are especially encouraged.** These awards are intended to provide funding for innovative pilot studies and/or small efficacy studies. Funds may not be used to support ongoing research projects. The Center encourages submissions relevant to any cancer disease site.

Through generous support from the President's Office and John and Jill Freidenrich, the Cancer Center expects to fund a number of one-year projects this year. Renewal for a second year is possible for particularly meritorious, clinically relevant projects with appropriate progress in the first year. Funds will be awarded on a competitive basis for up to \$50,000 per project. The number and amount of awards will depend upon the quality of the proposals received and the available funding. **Applications are due July 1, 2009 and awards will be announced on August 7, 2009.**

ELIGIBILITY

Stanford faculty working in highly cancer relevant areas of research are eligible to apply. If the PI is not a Cancer Center member, a brief letter of support from a Cancer Center member must accompany the application. The Cancer Center member sponsoring the application should be a project collaborator.

APPLICATION PROCEDURE

Application guidelines and cover page are available on the Cancer Center's website: <http://cancer.stanford.edu/>.

REVIEW AND REGULATIONS

A committee of Cancer Center senior faculty leaders and peer reviewers who will make recommendations for award funding will review proposals. Evaluation criteria include:

- (a) Scientific merit;
- (b) Relevance to clinical/translational cancer research;
- (c) Qualifications, experience and productivity of the applicant;
- (d) Collaboration within the cancer research community;
- (d) Project feasibility given facilities, budget, time and other resources available; and
- (e) Potential for future grants and/or publications.

Funding must be used for a project that can be completed in the designated period of the grant proposal. Grants are for one year, except when otherwise specified in the application and approved by the committee. No-cost extensions are possible with written requests.

Grant funds may be budgeted for: (a) equipment and supplies; (b) communications; (c) personnel for research assistance; and (d) other purposes deemed necessary for the successful execution of the proposed project.

Unused funds will revert to the Stanford Cancer Center. All proposed expenses must conform to the general policies of the University and the Stanford Cancer Center.

Research involving animals or human subjects must be reviewed in accordance with the University's general assurances and HIPAA. Projects involving human subjects must be submitted to an Institutional Review Board (IRB). Intervention studies and clinical protocols must be reviewed and approved by the Protocol Review Committee (PRC). Projects must have appropriate approvals from the IRB and PRC prior to receiving funding. Appropriate animal care and use forms must also be filed and approved. All investigators and all persons named on the budget page must have certification of training in the protection of human subjects.

A final progress report shall be submitted 15 months after the start date. This report must be submitted at the conclusion of the grant period, or earlier, if the recipient of the grant is leaving the University.